TL;DR
- Company: Pharmathen International S.A., a sterile-injectable manufacturing site in Evrou, Greece.
- Date: Warning letter 320-26-80 issued May 27, 2026; posted to FDA's public database June 16, 2026.
- Classification: CGMP / Finished Pharmaceuticals / Adulterated, under 501(a)(2)(B) of the FD&C Act.
- Key citations: Failed airflow studies on a sterile filling line (211.113(b)), inadequate investigation of sterility and particulate failures (211.192), pressure-differential and facility-monitoring failures (211.42(c)(10)), and undocumented lab records (211.160(a)).
- Consequence: Firm suspended U.S. manufacturing in November 2025, its customers recalled affected injectable and suspension products, and the site has sat on Import Alert 66-40 since April 23, 2026.
| Company | Location | Letter # | Issued | Issuing Office | Inspection Dates | Classification |
|---|---|---|---|---|---|---|
| Pharmathen International S.A. | Industrial Park, Sapes Rodopi Prefecture, Evrou, Greece | 320-26-80 (MARCS-CMS 723680) | May 27, 2026 | CDER | November 10–21, 2025 | CGMP / Finished Pharmaceuticals / Adulterated |
Air that should move in one direction, moving in another. FDA investigators watched smoke bounce off an operator's chest and drift back into a sterile filling zone during a simulation test at Pharmathen's Greek manufacturing site. That single observation, documented in the FDA Warning Letter 320-26-80, May 27, 2026, became the anchor for a four-part citation that ended with the company suspending all U.S. drug production at the facility.
Pharmathen International S.A., FEI 3009961173, manufactures sterile injectable and suspension drug products at its Sapes Rodopi Prefecture facility in Evrou, Greece. FDA inspected the site November 10–21, 2025. The firm submitted a response to its Form FDA 483 on December 15, 2025. FDA reviewed that response in detail and found it insufficient on every major point.
What FDA found: the CFR-by-CFR breakdown
The letter documents four distinct regulatory failures.
21 CFR 211.113(b) — failure to prevent microbiological contamination. FDA's airflow visualization review found that smoke studies on the firm's restricted access barrier system (RABS) filling line did not demonstrate unidirectional airflow. During one simulation, airflow was observed exiting the filling line, bouncing off an operator, and reentering the area, according to the FDA Warning Letter. Inspectors also found multiple instances of gram-negative microbes in ISO 5 (Grade A) air samples, which FDA calls "highly atypical" for an aseptic processing environment, plus operators exhibiting poor aseptic technique, including failing to discard exposed vials after a fallen-vial intervention.
21 CFR 211.192 — failure to investigate discrepancies. FDA found the firm's investigations into sterility failures and environmental monitoring excursions lacked scientific rationale to support root causes. The letter cites a specific example: a batch of injectable product with an in-process visible-particulate rejection rate FDA calls "very high," alongside recurring sterility and media-fill failures the firm had experienced over the preceding five years without implementing effective corrective action.
21 CFR 211.42(c)(10) — inadequate facility design and control. Pressure differentials in the aseptic filling rooms were found to run lower than adjacent, less-clean spaces, a configuration that lets contaminants migrate toward the more sterile zone rather than away from it. Compounding this, the firm's monitoring devices displayed real-time data only, with no data storage, meaning pressure excursions that occurred when no one was watching went undocumented, with no alarm history retained.
21 CFR 211.160(a) — undocumented laboratory controls. Investigators found microbial plates in incubators lacking documentation tying raw data to sample preparation and identification numbers. In its response, the firm acknowledged discarding sterility test results for 16 batches after identifying missing documentation, according to the same letter.
FDA also flagged a standalone data-integrity failure, citing its guidance on Data Integrity and Compliance With Drug CGMP, and recommended the firm engage a CGMP consultant under 21 CFR 211.34 before resuming any U.S.-bound manufacturing.
Why FDA called every corrective response "inadequate"
Four separate times in this letter, FDA reviews the firm's proposed corrective action and rejects it as insufficient. On the airflow failures, Pharmathen committed to training and a gap assessment; FDA said that didn't address the scope of the operator-oversight failures or establish a root cause. On the investigation failures, the firm proposed a statistical-sampling third-party review; FDA called the sampling approach inadequate given "the significance of the questionable practices documented during the inspection." On facility design, the firm acknowledged its legacy layout allowed inappropriate airflow direction but gave no CAPA detail on the fix. On lab documentation, the firm's response was limited to discarding the flawed sterility tests, without a holistic assessment of how far the documentation problem extended.
That pattern matters for how compliance teams should read this letter. FDA isn't just listing observations; it's demonstrating, section by section, what an inadequate response looks like even when a firm acknowledges the underlying problem. Acknowledgment without a scoped, root-cause-driven remediation plan does not close a citation. Teams drafting their own 483 or warning-letter responses can use this letter as a negative template: each rejected response either lacked a defined scope, skipped root-cause analysis, or failed to address systemic (versus one-off) causes.
What happened after the inspection
FDA held a teleconference with the firm recommending removal of affected injection and suspension batches from the U.S. market. The firm agreed to stop manufacturing and distributing all U.S.-bound drugs indefinitely pending completion and third-party assessment of its CAPAs, and recommended its drug sponsors initiate voluntary recalls. Those sponsors subsequently issued voluntary recalls of the affected injection and suspension products "due to lack of assurance of sterility," per the warning letter's own account.
FDA placed all drugs and drug products offered for import from this firm on Import Alert 66-40 on April 23, 2026, roughly five months after the inspection closed and about a month before the warning letter itself posted. That alert authorizes detention without physical examination for any shipment from the listed facility. The firm also acknowledged suspending manufacturing in November 2025, effectively during the inspection window itself.
What compliance teams should take from it
This letter is a useful reference point for two reasons beyond its own facts. First, it shows FDA applying the same rejected-response pattern across airflow, investigations, facility monitoring, and documentation, suggesting inspectors are looking for coherence across a firm's entire quality system, not isolated fixes to isolated findings. A firm that treats a smoke-study failure as a facilities problem and a documentation gap as a training problem, without asking whether both trace back to the same underlying quality-unit authority gap, is likely to get the same "inadequate" verdict FDA gave here.
Second, the timeline is instructive: inspection closed November 2025, manufacturing suspended during the inspection, Import Alert placed April 2026, warning letter posted publicly in June 2026. Firms and their customers monitoring supply-chain risk should not wait for the public warning letter to act; recalls and import restrictions in this case preceded the letter's public posting by weeks. Audit programs tracking CDMO and API supplier risk should build in checks for FDA import-alert status and voluntary-recall activity independent of warning-letter publication dates, since the public letter is often the last, not the first, signal of a problem.
FAQ
What products does the Pharmathen warning letter affect?
The letter covers sterile injectable and suspension drug products manufactured at the firm's Evrou, Greece facility. FDA redacts specific product identifiers in the public letter as (b)(4).
Is Pharmathen currently allowed to ship product to the U.S.?
The firm's products are on Import Alert 66-40 as of April 23, 2026, which allows FDA to detain shipments without physical examination. The firm also states it suspended U.S. manufacturing at this facility in November 2025.
Did this warning letter lead to a product recall?
Yes. Per the letter, the firm's drug sponsors issued voluntary recalls of the affected injection and suspension products after Pharmathen recommended the action, citing lack of assurance of sterility.
Source: FDA Warning Letter 320-26-80, May 27, 2026. Byline: The Argus Regulatory Analysis Team. Published 2026-07-05.